The Promise and Pitfalls of Polygenic Risk Scores in Healthcare

Polygenic risk scores (PRS) represent a significant advancement in genetic research, providing a numerical estimate of an individual's genetic predisposition to complex diseases by aggregating the effects of numerous genetic variants. Dr. Anna CF Lewis, a bioethicist at Harvard Medical School, explains that these scores are calculated by weighing the contributions of many single-nucleotide variants linked to specific diseases, such as coronary artery disease. This method contrasts with traditional genetic tests that focus on single mutations, allowing for a more comprehensive assessment of genetic risk.

Technology NetworksResearchers Find Polygenic Risk Scores Improve Accuracy of CVD Risk Prediction

The integration of PRS into healthcare holds the potential to personalize medical interventions and preventive strategies. By identifying individuals at higher genetic risk for conditions like heart disease and diabetes, healthcare providers could implement early interventions, including lifestyle modifications and preventive treatments. Recent research presented at the American Heart Association Conference 2025 indicates that incorporating PRS into cardiovascular disease (CVD) risk prediction tools, such as the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) tool, significantly enhances predictive accuracy across diverse populations. This improvement could lead to better identification of high-risk individuals, ultimately saving lives and improving overall population health.

Researchers Find Polygenic Risk Scores Improve Accuracy of CVD Risk PredictionTechnology Networks

Despite their promise, the application of PRS raises several ethical and practical concerns. As these scores become more integrated into routine healthcare, issues such as genetic discrimination and the implications of using PRS for embryo selection emerge. Dr. Lewis warns against genetic fatalism, the belief that genetic predispositions rigidly determine health outcomes, emphasizing the need for ethical reflection to accompany scientific advancements. Furthermore, the integration of PRS into clinical practice requires careful evaluation of their predictive power, fairness, reliability, and real-world effectiveness to ensure that their potential benefits are realized without compromising individual rights.

Technology Networks

While the research supports the utility of PRS in improving CVD risk prediction, there remains a gap in understanding how best to implement these scores in clinical settings. The ethical landscape surrounding their use continues to evolve, necessitating proactive engagement and transparent policy development to address emerging concerns.

Technology Networks

• “Our findings show that incorporating polygenic risk scores into clinical practice can significantly improve the predictive power of tools like PREVENT across diverse populations, making risk assessment more equitable and precise.” — Professor Sir Peter Donnelly, Co-Founder and CEO of Genomics.

Researchers Find Polygenic Risk Scores Improve Accuracy of CVD Risk Prediction

• “It is hoped that polygenic risk scores can identify the most effective ways to incorporate their use into healthcare,” — Dr. Anna CF Lewis, Bioethicist.

Technology Networks

The ongoing research into polygenic risk scores illustrates their potential to transform healthcare by enhancing disease risk prediction and personalizing preventive strategies. However, as the field evolves, it is crucial to address the ethical implications and practical challenges associated with their use to ensure that advancements in genetic research benefit individuals and society as a whole.

Technology Networks